Products - Children and young people | Topic

Showing 22 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
Status: In developmentRemove ‘Status: In development’ filter

The MAGEC system for spinal lengthening in children with scoliosis
Status:
In development | In consultation
Programme:
Medical technologies guidance
Consultation end date:
24 June 2020
Expected publication date:
15 September 2020
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)
Status:
In development
Programme:
NICE guideline
Expected publication date:
7 April 2021
Babies, children and young people's experience of healthcare
Status:
In development
Programme:
NICE guideline
Expected publication date:
7 April 2021
Looked-after children and young people
Status:
In development
Programme:
NICE guideline
Expected publication date:
26 April 2021
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education
Status:
In development
Programme:
NICE guideline
Expected publication date:
12 May 2021
Social, emotional and mental wellbeing in primary and secondary education
Status:
In development
Programme:
NICE guideline
Expected publication date:
9 November 2021
Epilepsies in children, young people and adults
Status:
In development
Programme:
NICE guideline
Expected publication date:
16 November 2021
Self harm: assessment, management and preventing recurrence
Status:
In development
Programme:
NICE guideline
Expected publication date:
26 January 2022
Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fenfluramine for treating Dravet syndrome [ID1109]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and young people Products

Filter

Product type
1 selected

Guidance programme

Status
1 selected

New and updated

Showing 22 products

The MAGEC system for spinal lengthening in children with scoliosis

Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

Babies, children and young people's experience of healthcare

Looked-after children and young people

Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

Social, emotional and mental wellbeing in primary and secondary education

Epilepsies in children, young people and adults

Self harm: assessment, management and preventing recurrence

Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336

Fenfluramine for treating Dravet syndrome [ID1109]

Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update)

Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]

Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]

Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]

Children and young people Products

Filter

Product type1 selected

Guidance programme

Status1 selected

New and updated

Showing 22 products

Product type
1 selected

Status
1 selected